arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

NOVAVAX INC

NVAX
$7.94 ▲ +0.20 (+2.58%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Bullish
auto_awesome

Analytical Summary

NOVAVAX INC shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.3B
Dividend Yield
Revenue Growth -79.1%
Op. Margin -11.1%
ROIC -11.8%
FCF / Share $-0.20
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -2.01
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$139.51M
↓ -79.1%
Net Income Profit after all expenses
$-9.49M
↓ -154.2%
Operating Margin Operating profit as % of sales
-11.1%
↓ -214.4% 94th
FCF / Share Free cash flow per share
$-0.20
↑ +82.8%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
66
Financial Health
92
Cash Quality
13

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters